Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334412 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9762476 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9762486 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9761663 | 0.95 | ADORA2A (0.90) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9761636 | 0.95 | ADORA2A (0.90) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL10585629 | 0.94 | ADORA2A (0.88) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL10585648 | 0.94 | ADORA2A (0.88) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9763035 | 0.93 | ADORA2A (0.87) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9763054 | 0.93 | ADORA2A (0.87) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9762024 | 0.92 | ADORA2A (0.85) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515885-A | — | — | 2002-05-28 | — | — | JP | claimed |
| EP-0880353-A4 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS INC (US) | 2001-04-18 | — | — | EP | claimed |
| EP-0983768-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Nippon Shinyaku Co., Ltd. (JP) | 2000-03-08 | — | — | EP | claimed |
| US-5998423-A | IN SKIN OR HAIR; ADMINISTERING ADENOSINE RECEPTOR ANTAGONIST | THERASYS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| EP-0880353-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | Therasys, Inc. (US) | 1998-12-02 | — | — | EP | claimed |
| WO-1998015276-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS, INC. (US) | 1998-04-16 | — | — | WO | claimed |
| US-5034381-A | Antagonist | CIBA-GEIGY CORPORATION (US) | 1991-07-23 | — | — | US | claimed |
| EP-0323807-A2 | Certain 2-substituted adenosine derivatives | CIBA-GEIGY AG (CH) | 1989-07-12 | — | — | EP | claimed |
| JP-1265100-A | — | — | None | — | — | JP | disclosed |
| US-20070059269-A1 | Administration of 8-hexadecene-1,16-dicarboxylic acid for promoting cohesion of the epidermal horny layer | L'OREAL (FR) | 2007-03-15 | — | — | US | disclosed |
| EP-1754513-A2 | Use of 8-hexadecene-1,16-dicarboxylic acid as a care agent for promoting the horny layer cohesion | L'OREAL (FR) | 2007-02-21 | — | — | EP | disclosed |
| EP-0983768-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Nippon Shinyaku Co., Ltd. (JP) | 2000-03-08 | — | — | EP | disclosed |
| EP-0689405-A4 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA INC (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0689405-A1 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021195-A1 | METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE | GENSIA, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5034381-A | Antagonist | CIBA-GEIGY CORPORATION (US) | 1991-07-23 | — | — | US | disclosed |
| JP-H01265100-A | 2-SUBSTITUTED ADENOSINE DERIVATIVE | CIBA GEIGY AG | 1989-10-23 | — | — | JP | disclosed |
| EP-0323807-A2 | Certain 2-substituted adenosine derivatives | CIBA-GEIGY AG (CH) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059269-A1 | Administration of 8-hexadecene-1,16-dicarboxylic acid for promoting cohesion of the epidermal horny layer | DSG1, CUTA, DSC1 | ADORA2A 4168/4885ADORA2B 4407/4885ADORA3 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.